The 34 references in paper L. Toporkova B., A. Petuhova A., I. Gileva P., I. Orlovskaya A., Л. Топоркова Б., А. Петухова А., И. Гилева П., И. Орловская А. (2014) “РЕКОМБИНАНТНЫЙ БЕЛОК ВИРУСА НАТУРАЛЬНОЙ ОСПЫ НЕЙТРАЛИЗУЕТ ЭФФЕКТЫ ФАКТОРА НЕКРОЗА ОПУХОЛЕЙ НА МОДЕЛИ КОСТНОМОЗГОВОГО ГЕМОПОЭЗА МЫШЕЙ BALB/С // RECOMBINANT PROTEIN OF VARIOLA VIRUS ABOLISHES THE EFFECTS OF TUMOR NECROSIS FACTOR UPON MARROW HEMATOPOIESIS IN BALB/С MICE” / spz:neicon:mimmun:y:2010:i:5:p:297-304

1
Гилева И.П., Рязанкин И.А., Максютов З.А., Тотменин А.В., Агеенко В.А., Нестеров А.Е., Щелкунов С.Н. Рекомбинантная плазмидная ДНК pFastBac-G2R, содержащая фрагмент генома вируса натуральной оспы, кодирующий белок-аналог рецептора TNF, и штамм бакуловируса BVi67, продуцирующий растворимый рецептор TNF вируса натуральной оспы // Рос. патент No 2241754. – 2003.
(check this in PDF content)
2
Гилева И.П., Рязанкин И.А., Максютов З.А., Тотменин А.В., Лебедев Л.Р., Нестеров А.Е., Агеенко В.А., Щелкунов С.Н., Сандахчиев Л.С. Сравнительное изучение свойств ортопоксвирусных растворимых рецепторов фактора некроза опухолей // Доклады РАН. – 2003. – Т. 390. – С. 160-164.
(check this in PDF content)
3
Гилева И.П., Рязанкин И.А., Непомнящих Т.С., Тотменин А.В., Максютов З.А., Лебедев Л.Р., Афиногенова Г.Н., Пустошилова Н.М., Щелкунов С.Н. Экспрессия генов TNFсвязывающих белков ортопоксвирусов в клетках насекомых и изучение свойств рекомбинантных белков // Молекулярная биология. – 2005. – Т. 39. – С. 1.
(check this in PDF content)
4
Гилева И.П., Непомнящих Т.С., Рязанкин И.А., Щелкунов С.Н.. Рекомбинантный TNF- связывающий белок вируса натуральной оспы как потенциальный TNF-антагонист нового поколения // Биохимия. – 2009. – Т. 74. – C. 1664-1671.
(check this in PDF content)
5
Гилева И.П., Малкова Е.М., Непомнящих Т.С., Виноградов И.В., Лебедев Л.Р., Кочнева Г.В., Гражданцева А.А., Рябчикова Е.И., Щелкунов С.Н. Изучение действия TNFсвязывающего белка вируса натуральной оспы на развитие ЛПС-индуцированного эндотоксического шока // Цитокины и воспаление. – 2006. – Т. 5. – С. 44–-48.
(check this in PDF content)
6
Лебедев Л.Р., Рязанкин И.А., Сизов А.А., Агеенко В.А., Одегов В.Н., Афиногенова Г.Н., Щелкунов С.Н. Способ очистки антагонистов фактора некроза опухолей и исследование их некоторых свойств // Биотехнология. – 2001. – No 6. – С. 14-18.
(check this in PDF content)
7
Щелкунов С.Н. Иммуномодуляторные белки ортопоксвирусов // Молекулярная биология. – 2003. – Т. 37. – С. 41-53.
(check this in PDF content)
8
Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., Genovese M.C., Wasko M.C., Moreland L.W., Weaver A.L., Harkenson J., Fink B.K. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis // N. Engl. J. Med. – 2000. – Vol. 343. – P. 1586-1593.
(check this in PDF content)
9
Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding // Anal. Biochem. – 1976. – Vol. 72. – P. 248-254.
(check this in PDF content)
10
Broxmeyer H.E., Williams D.E., Lu L., Cooper S., Anderson S.L., Beyer G.S., Hoffman R., Rubin B.Y. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma // J. Immunol. – 1986. – Vol. 136. – P. 4487-4495.
(check this in PDF content)
11
Calabrese L.H., Zein N., Vassilipoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection // Ann. Rheum. Dis. – 2004. – Vol. 63 (supp. 2). – P. 18-24.
(check this in PDF content)
12
Caux C., Favre C., Saeland S., Duvert V., Durand I., Mannoni P., Banchereau J. Potentiation of early hematopoiesis by Tumor Necrosis Factor-α is followed by inhibition of granulopoietic differentiation and proliferation // Blood. – 1991. – Vol. 78. – P. 635-644.
(check this in PDF content)
13
Drugs for rheumatoid arthritis // Treatment Guideline the Medical Letter. – 2005. – Vol. 3. – P. 83-90.
(check this in PDF content)
14
Fahlman C., Jacobsen F.W., Veiby O.P., McNiece I.K., Blomhoff H.K., Jacobsen S.E.W. Tumor Necrosis Factor potently enhances in vitro macrophage production from primitive murine hematopoietic progenitor cells in combination with Stem Cell Factor and Interleukin-7: novel stimulatory role of p55 TNF receptor // Blood. – 1994. – Vol. 84. – P. 1528-1533.
(check this in PDF content)
15
Fukaya H., Xiao W., Inaba K., Suzuki Y., Hirokawa M., Kawabata Y., Komatsuda A., Endo T., Kishimoto H., Takada G., Sawada K. Codevelopment of dendritic cells along with erythroid differentiation from human CD34+ cells by tumor necrosis factor-α // Exp. Hematol. – 2004. – Vol. 32. – P. 450-460.
(check this in PDF content)
16
Gileva I.P., Nepomnyashchikh T.S., Antonets D.V., Lebedev L.R., Kochneva G.V., Grazhdantseva A.V., Shchelkunov S.N. Properties of the recombinant TNF-binding proteins from variola, monkeypox, and cowpox viruses are different // BBA – Proteins and Proteomics. – 2006. – Vol. 1764, N. 11. – P. 1710-1718.
(check this in PDF content)
17
Hasegawa A., Takasaki W., Greene M.I., Murali R. Modifying TNFα for therapeutic use: A perspective on the TNF receptor system // Mini. Rev. Med. Chem. – 2001. – Vol. 1. – P. 5-16.
(check this in PDF content)
18
Johnson C. S., Chang M.-J., Furmanski P. In Vivo Hematopoietic Effects of Tumor Necrosis Factor-a in Normal and Erythroleukemic Mice: Characterization and Therapeutic Applications // Blood. – 1988. – Vol. 72. – P. 1875-1883.
(check this in PDF content)
19
Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., Scallon B., Moore M.A., Vilcek J., Daddona P., Ghrayeb J. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody // Mol. Immunol. – 1993. – Vol. 30. – P. 1443-1453.
(check this in PDF content)
20
Liu J.J., Hou S.C., Shen C.K. Erythroid gene suppression by NF-kappa B // J. Biol. Chem. – 2003. – Vol. 278. – P. 19534-19540.
(check this in PDF content)
21
Lo E., Rezaik K., Evans A.T., Madariaga M.G., Phillips M., Brobbey W., Schwartz D.N., Wang Y., Weinstein R.A., Trenholm G.M. Why don’t they listen? Adherence to recommendations of infectious diseases consultations // Clin. Infect. Dis. – 2004. – Vol. 40. – P. 636-637.
(check this in PDF content)
22
Mc Devitt H., Munson S., Ettingen R., Wu A. Multiple roles for tumor necrosis factor-α and lymphotoxin α/β in immunity and autoimmunity // Arthritis Res. – 2002. – Vol. 4 (supp.).
(check this in PDF content)
23
McFadden G., Murphy P.M. Host-related immunomodulators encoded by poxviruses and herpesviruses // Curr. Opin. Microbiol. – 2000. – Vol. 3. – P. 371-373.
(check this in PDF content)
24
Mohler K.M., Torrance D.C., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., Madani H., Widmer M.B. Soluble tumor necroses factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carries and TNF antagonists // J. Immunol. – 1993. – Vol. 151. – P. 1548-1561.
(check this in PDF content)
25
Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.I., Ettinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., Blosch C.M. Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein // N. Engl. J. Med. – 1997. – Vol. 337. – P. 141-147.
(check this in PDF content)
26
Papadaki H., Kritikos H., Valatas V., Boumpas D., Eliopoulos G.. Anemia of chronic diseases in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy // Blood. – 2002. – Vol. 100. – P. 474-482.
(check this in PDF content)
27
Roodman G., Bird A., Hutzler D., Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells // Exp Hematol. – 1987. – Vol. 15. – P. 928-935.
(check this in PDF content)
28
Rusten L.S., Jacobsen S.E. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors // Blood. – 1995. – Vol. 85. – P. 989-996.
(check this in PDF content)
29
Scallon B.J., Trinh T., Nedelman M., Brennan F.M., Feldmann M, Ghrayeb J. Functional comparisons of different tumor necroses factor receptor/IgG fusion proteins // Cytokine. – 1995. – Vol. 7. – P. 759-770.
(check this in PDF content)
30
Siegel S.A., Shealy D.J., Nakada M.T., Le J., Woulfe D.S., Probert L., Kollias G., Ghrayeb J., Vilcek J., Daddona P.E. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo // Cytokine. – 1995. – Vol. 7. – P. 1525.
(check this in PDF content)
31
Skobin V., Jelkmann W., Morschakova E., Pavlov A.D., Schlenke P. Tumor necrosis factor-alfa and TNF-beta inhibit clonogenicity of mobilized human hematopoietic progenitors // J. Interferon Cytokin Res. – 2000. – Vol. 20. – P. 507-510.
(check this in PDF content)
32
Urbaschek R., Mannel D.N., Urbaschek B. Tumor necrosis factor induced stimulation of granulopoiesis and radioprotection // Lymfokine Res. – 1987. – Vol. 6. – P. 179-186.
(check this in PDF content)
33
Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Bizbara C.A., Teoh L.A., Fischoff S.A., Chartash E.K. Adalimumab. A fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial // Arthritis and Rheumatism – 2003. – Vol. 48. – P. 35-45.
(check this in PDF content)
34
Xiao W., Koizumi K., Nishio M., Endo T., Osawa M., Fujimoto K., Sato I., Sakai T., Koike T., Sawada K. Tumor necrosis factor-alpha inhibits generation of glycophorin A+ cells by CD34+ cells. // Exp. Hematol. – 2002. – Vol. 30. – P. 1238-1247.
(check this in PDF content)